Search

Search Results

1. Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes

   The emergence of precision medicine and our latest understanding of the biological characteristics of ovarian cancer (OC) have led to the discovery...

   Khalid El Bairi, Ouissam Al Jarroudi, Said Afqir in Ovarian Cancer Biomarkers

   Chapter 2021
   

2. Targeting PI3K in cancer: mechanisms and advances in clinical trials

   Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which...

   **g Yang, Ji Nie, ... **awei Wei in Molecular Cancer

   Article Open access 19 February 2019
   

3. Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy

   Background

   The critical role of phosphoinositide 3-kinase (PI3K) activation in tumor cell biology has prompted massive efforts to develop PI3K...

   **n Peng, Shaolu Zhang, ... Dexin Kong in Journal of Experimental & Clinical Cancer Research

   Article Open access 29 November 2021
   

4. The role of PI3Kγ in the immune system: new insights and translational implications

   Over the past two decades, new insights have positioned phosphoinositide 3-kinase-γ (PI3Kγ) as a context-dependent modulator of immunity and...

   Stephen M. Lanahan, Matthias P. Wymann, Carrie L. Lucas in Nature Reviews Immunology

   Article 23 March 2022
   

5. Clinical implications of genomic alterations in metastatic prostate cancer

   There has been a rapid expansion in treatment options for the management of metastatic prostate cancer, but individual patient outcomes can be...

   Takayuki Sumiyoshi, Kim N. Chi, Alexander W. Wyatt in Prostate Cancer and Prostatic Diseases

   Article 15 January 2021
   

6. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance

   Homologous recombination (HR) repair deficiency impairs the proper maintenance of genomic stability, thus rendering cancer cells vulnerable to loss...

   Dae-Seok Kim, Cristel V. Camacho, W. Lee Kraus in Experimental & Molecular Medicine

   Article Open access 25 January 2021
   

7. Overview of Current Type I/II Kinase Inhibitors

   Research on kinase-targeting drugs has made great strides over the last 30 years and is attracting greater attention for the treatment of yet more...

   Zheng Zhao, Philip E. Bourne in Next Generation Kinase Inhibitors

   Chapter 2020
   

8. A clear cancer cell line (150057) derived from human endometrial carcinoma harbors two novel mutations

   Background

   Cell lines are extremely useful for both basic and clinical research. Thus, establishing endometrial cancer cell lines with malignant...

   Yu-Hsun Chang, Dah-Ching Ding in BMC Cancer

   Article Open access 03 November 2020
   

9. Emerging role of PTEN loss in evasion of the immune response to tumours

   Mutations in PTEN activate the phosphoinositide 3-kinase (PI3K) signalling network, leading to many of the characteristic phenotypic changes of...

   Thiago Vidotto, Camila Morais Melo, ... Jeremy A. Squire in British Journal of Cancer

   Article Open access 24 April 2020
   

10. Phospholipid Kinases

    Bernd Nürnberg, Sandra Beer-Hammer in Encyclopedia of Molecular Pharmacology

    Living reference work entry 2020
    

11. Relapsed Osteosarcoma Trial Concepts to Match the Complexity of the Disease

    Osteosarcoma relapses not only herald a very poor prognosis but also opportunities to treat this genetically diverse complex cancer in new ways. This...

    Damon R. Reed, Pooja Hingorani, Peter M. Anderson in Current Advances in Osteosarcoma

    Chapter 2020
    

12. Current and emerging therapies for primary central nervous system lymphoma

    Primary central nervous system (CNS) lymphoma (PCNSL) is a rare type of extranodal lymphoma exclusively involving the CNS at the onset, with diffuse...

    Yan Yuan, Tianling Ding, ... Tong Chen in Biomarker Research

    Article Open access 06 May 2021
    

13. Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer

    PARP inhibitors are a group of inhibitors targeting poly(ADP-ribose) polymerases (PARP1 or PARP2) involved in DNA repair and transcriptional...

    Yi-xin Chen, Li-ming Tan, ... Zhao-qian Liu in Acta Pharmacologica Sinica

    Article 15 February 2021
    

14. Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine

    Head and neck squamous cell carcinoma (HNSCC) develops in the mucosal lining of the upper aerodigestive tract, principally as a result of exposure to...

    Linah A. Shahoumi, W. Andrew Yeudall in EPMA Journal

    Article 20 July 2019
    

15. De novo mutation of cancer-related genes associates with particular neurodevelopmental disorders

    Abstract

    Epidemiological studies have shown an increased prevalence of cancer in some patients with neurodevelopmental disorder (NDD); however, the...

    Bin Li, Kuokuo Li, ... **chen Li in Journal of Molecular Medicine

    Article 12 October 2020
    

16. Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

    Across a broad range of human cancers, gain-of-function mutations in RAS genes ( HRAS , NRAS , and KRAS ) lead to constitutive activity of oncoproteins...

    Daolin Tang, Guido Kroemer, Rui Kang in Molecular Cancer

    Article Open access 04 October 2021
    

17. The Prospects of Therapeutic Potential and Drug Development Targeting Autophagy in Cancer

    Autophagy is a self-protection mechanism of cells. Cells can degrade damaged organelles and macromolecules in this way to guarantee the growth and...

    **ku Bao, Bo Liu, Chuanfang Wu in Autophagy: Biology and Diseases

    Chapter 2020
    

18. Molecular profiling for precision cancer therapies

    The number of druggable tumor-specific molecular aberrations has grown substantially in the past decade, with a significant survival benefit obtained...

    Eoghan R. Malone, Marc Oliva, ... Lillian L. Siu in Genome Medicine

    Article Open access 14 January 2020
    

19. Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies

    Venetoclax has been approved by the United States Food and Drug Administration since 2016 as a monotherapy for treating patients with...

    **aoYan Yue, Qingxiao Chen, **gSong He in Cancer Cell International

    Article Open access 29 October 2020
    

20. Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment

    Immune checkpoint inhibitors (ICIs) have revolutionized the clinical management of multiple tumours. However, only a few patients respond to ICIs,...

    Giulia Petroni, Aitziber Buqué, ... Lorenzo Galluzzi in Nature Reviews Drug Discovery

    Article 15 March 2022